Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

Investor Overview

Investor Overview

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

News Releases

Date Title and Summary Additional Formats
Toggle Summary Charles River Laboratories Adds George Llado to Board of Directors
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado , Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to its Board of Directors. Mr.
View HTML
Toggle Summary Charles River Laboratories Schedules Third-Quarter 2020 Earnings Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 13, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2020 financial results on Thursday, October 29 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday,
View HTML
Toggle Summary Charles River Laboratories to Present at September Investor Conferences
WILMINGTON, Mass. --(BUSINESS WIRE)--Sep. 8, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including: Wells Fargo 2020 Healthcare Conference on Wednesday, September 9 th , at 8:40 a.m.
View HTML
Toggle Summary Charles River Laboratories Announces Second-Quarter 2020 Results
– Second-Quarter Revenue of $682.6 Million – – Second-Quarter GAAP Earnings per Share of $1.34   and Non-GAAP Earnings per Share of $1.58 – – Increases 2020 Guidance – – Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market – WILMINGTON, Mass. --(BUSINESS WIRE)--Aug.
View HTML

Featured Report

2019 Annual Report (PDF)